A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

This is an open-label, multicenter study to evaluate the safety of weekly SC administration of pegzilarginase over 12 months in subjects with ARG1-D. The study consists of a screening period of up to 4 weeks, a subsequent 12-month treatment period, and a Safety Follow-Up Visit 2 weeks after the last treatment.

Inclusion Criteria:Prior enrollment in pegzilarginase clinical studies, with completion of treatment or continued dosing as of the study termination dateWritten informed consent by subject/parent/legal guardian, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocolNegative pregnancy test within 7 days prior to dosing in childbearing subjects if they are sexually activeIf the subject (male or female) is engaging in sexual activity that could lead to pregnancy, must be surgically sterile, post-menopausal (female), or must agree to use a highly effective method of birth control during the study and for a minimum of 30 days after the last study drug administration. Highly effective methods of contraception include combined (estrogen and progestogen-containing) hormonal contraception associated with inhibition of ovulation, progesterone-only hormonal contraception associated with inhibition of ovulation, intrauterine device, or intrauterine hormone-releasing systemExclusion Criteria:Subjects with acute or ongoing hyperammonemia within 6 weeks of the first doseSubjects with medical conditions or underlying issues that, in the opinion of the Investigator, would preclude participation in the study